Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare disease-free survival (DFS) of patients
with triple negative breast cancer randomised to treatment with standard adjuvant
chemotherapy alone or to standard adjuvant chemotherapy followed by 1 year of Capecitabine
(Xeloda) metronomic therapy.